Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Netherlands Blocks Dr. Reddy’s Drug Shipment Bound For Brazil

This article was originally published in PharmAsia News

Executive Summary

Dutch authorities seized a shipment of drugs from Dr. Reddy's Laboratories to Brazil, the first time a shipment of a major Indian drug maker has been seized for patent infringement. The drugs in the shipment were generics worth $500,000, composed primarily of losartan for treating high blood pressure and patented in The Netherlands by DuPont of U.S. as Cozaar. India's commerce secretary called the move an act of piracy and complained to the European Commission. Many shipments of small- and medium-sized Indian makers of bulk drugs had reported previous seizures by Dutch authorities of shipments bound for other countries. Indian lawyers argue the drugs are not destined for Dutch consumers and should not be blocked if they do not violate the patent laws of India or the nation of destination. (Click here for more

You may also be interested in...



EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand

Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.

2020 US Beauty May Be Headed For Record Declines, But There Are COVID-19 Opportunities

Kline & Company’s worst-case scenario – which it says is looking more and more likely – has the US cosmetics and personal-care market declining by as much as 8.1% in 2020. However, Kline, Mintel and other market intelligence firms say there are opportunities available to companies struggling to weather the COVID-19 storm.

UsernamePublicRestriction

Register

SC069829

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel